Premium
Abnormal neurotransmitter metabolite levels in Alzheimer patients with a delirium
Author(s) -
van der Cammen Tischa J.M.,
Tiemeier Henning,
Engelhart Marianne J.,
Fekkes Durk
Publication year - 2006
Publication title -
international journal of geriatric psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.28
H-Index - 129
eISSN - 1099-1166
pISSN - 0885-6230
DOI - 10.1002/gps.1569
Subject(s) - homovanillic acid , serotonergic , delirium , neurotransmitter , dopaminergic , metabolite , medicine , dopaminergic pathways , cerebrospinal fluid , alzheimer's disease , psychology , neurochemistry , endocrinology , dopamine , serotonin , disease , central nervous system , neurology , psychiatry , receptor
Background Delirium is a complex neuropsychiatric syndrome with an acute onset and fluctuating course. Several studies have suggested the presence of disturbed cholinergic, dopaminergic and serotonergic pathways in delirium as well as in Alzheimer's disease. Abnormal concentrations of amino acids and of neurotransmitter metabolites have been found in plasma, platelets and cerebrospinal fluid of AD patients, and in plasma and CSF of patients with a delirium. The aim of this study was to investigate amino acid and neurotransmitter metabolite levels in plasma of AD patients with a concurrent delirium. Methods In a case‐control study of patients suffering from Alzheimer's disease (AD) with concurrent delirium, we investigated the contribution of delirium to some biochemical parameters in blood. We compared plasma amino acid and neurotransmitter metabolite levels of 17 delirious AD patients with those of 17 age‐ and gender‐matched non‐delirious AD patients and 29 age‐ and gender‐matched controls. Results Homovanillic acid (HVA) and 5‐hydroxyindoleacetic acid (5‐HIAA) levels were higher in delirious AD patients than in controls, but only HVA concentrations were higher in delirious AD patients than in non‐delirious AD patients. Conclusions Our findings suggest that central dopaminergic and serotonergic turnover are increased in AD patients with delirium and that the high dopaminergic turnover might reflect the consequences of delirium. Copyright © 2006 John Wiley & Sons, Ltd.